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Should the Guidelines for the
Assessment of the Severity of
Functional Mitral Regurgitation
Be Redeﬁned?
The 2012 guidelines for the management of valvular heart
disease by the European Society of Cardiology (ESC) (1)
recommend that for functional mitral regurgitation (MR), an
effective regurgitant oriﬁce area (EROA) of >20 mm2 should
be considered severe; however, an EROA of >40 mm2 is used
as the cutoff for degenerative MR.
Several nonrandomized studies have shown that cardiac
mortality is increased in the presence of functional MR and
reduced left ventricular (LV) ejection fraction (2). Patients with
an EROA of $20 mm2 have a lower 5-year survival rate and a
higher risk of congestive heart failure. This same association is
present for lesser degrees of MR; with an EROA of 1 to
19 mm2, there is an increased 5-year mortality rate and a high
risk of congestive heart failure. Current American College of
Cardiology/American Heart Association (ACC/AHA) (3) and
ESC guidelines (1) use a matrix of criteria for the diagnosis of
severe MR, as shown in Table 1. No single criterion in isolation
is sufﬁcient to establish a diagnosis of severe MR. EROA can be
calculated by the proximal isovelocity surface area (PISA) or by
measuring the MR volume or regurgitant volume by assessing
the LV volume and LV forward stroke volume. Most echo-
cardiography laboratories do not use the latter volumetric
technique because it is time-consuming and can be associated
with signiﬁcant errors due to unreliable endocardial edge
detection. In addition, calculations of forward stroke volume
may be inaccurate because they are generally based on theTable 1. Multiparameter Approach for Deﬁning
Severe Mitral Regurgitation
Qualitative
Color Doppler jet area >40% of the left atrium, wall-hugging jet of any
size, swirling in the left atrium
Doppler vena contracta width $0.7 cm
Systolic ﬂow reversal in the pulmonary veins
Quantitative
Regurgitant volume $60 ml/beat
Regurgitant fraction $50%
Effective regurgitant area >0.4
Additional supportive parameters
Left atrial size: enlarged
Left ventricular size: enlarged
E-wave dominant mitral ﬂow >1.2 m/s
Holosystolic Doppler signalfact, recent 3-dimensional echocardiography and computed
tomography data have shown that it is generally oval.
Thus, most clinical laboratories rely on ﬂow convergence
assessment or the PISA method to assess the EROA. However,
the use of the PISA to assess the EROA has also been shown to
be highly problematic: Table 2 lists >10 substantial limitations
to the PISA method. In addition to these limitations, reliance
on a single method to assess MR severity in functional MR
deviates from the wisdom of using multiple criteria to grade MR
severity, which was supported by the initial ACC/AHA
guideline committees and the American and the European
echocardiography societies.
Unlike degenerative MR, especially in the setting of a ﬂail
leaﬂet where MR severity is relatively ﬁxed, functional MR
varies with the patients’ hemodynamic status. Because func-
tional MR severity may be highly variable, patients should be
assessed while on optimal therapy (including revascularization
and/or cardiac resynchronization therapy) before classifying
them as severe.
The rationale for the ESC recommendations to lower the
threshold for grading MR severity in the setting of functional
MR is in part related to the adverse prognosis associated with
MR in patients with LV dysfunction. However, associations do
not always equal causation, therapeutic indications, or thera-
peutic beneﬁt. CAST (Cardiac Arrhythmia Suppression Trial)
serves as an example of why associated phenomena should not
be used as targets for treatment. For years, “it was known” that
ventricular ectopy in the setting of reduced LV function was
associated with a worse prognosis as well as being associated
with a higher incidence of sudden death. However, the CAST
clearly showed that treating this associated variable (premature
ventricular contractions) with antiarrhythmic agents increased
all-cause mortality and also serves as an example of why asso-
ciated phenomena should not be used as targets for treatment.Table 2. Limitations of the Proximal Isovelocity Surface Area Method
Limited accuracy for eccentric jet
Difﬁcult to judge
Precise location of mitral valve oriﬁce
Flow convergence shape
Assumes a hemispheric jet
Jet usually noncircular and often slit like
Shape affected by aliasing velocity
Shape affected by adjacent structures
Errors in measurement are ampliﬁed due to squaring in equation
Regurgitant ﬂow changes during systole
Not valid for multiple jets
Great interobserver variability and poor agreement, even among
experienced echocardiologists
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314Multiple trials demonstrate that for functional MR (ischemic or
nonischemic), surgery with revascularization or mitral valve repair or
replacement does not improve the 5-year survival rate (4). The only
therapies that are beneﬁcial for functional MR are those that
improve ventricular function such as beta-blockers and angiotensin-
converting enzyme inhibitors. Until now, moderate MR has been
deﬁned by an EROA of 0.20 to 0.39 mm2. Patients with 3þ to 4þ
MR who have moderate (2þ) residual MR after placement of a
MitraClip (Abbott Vascular, Abbott Park, Illinois) have reverse
remodeling, a decrease in LV end-diastolic volume from 159 ml to
141 ml (p < 0.001), a trend toward a decrease in end-systolic vol-
ume from 82 ml to 77 ml (p ¼ 0.07), and improvement in symp-
toms after 1 year (5). However, according to the recent ESC criteria,
patients with moderate functional MR would be classiﬁed inap-
propriately as having severe MR and would be candidates for further
intervention.
With the development of percutaneous techniques, there may be
an inclination to treat less severe degrees of MR in an attempt to
improve the status of patients with impaired LV function. However,
this approach is likely to be problematic. It will be difﬁcult to assess
improvement or treatment success (a decrease in MR) if patients
with an EROA of 20 to 30 mm2 are treated. Clinical follow-up and
assessment of improvement will be complicated by the patients’
underlying LV dysfunction. At present, if the criteria for MR
severity are to be reduced in the setting of functional disease, an
EROA threshold of 30 mm2 would be more amenable to deter-
mining whether the intervention reduced MR severity. With an
EROA between 20 and 30 mm2, it will be difﬁcult to discern
whether the intervention actually decreased MR severity, and even
more so if the EROA is 20 to 25 mm2. It is also important not to
use a single variable but to maintain the matrix of echocardiographic
Doppler parameters listed in Table 1, which have been the standard
used to deﬁne MR severity.
Any degree of MR worsens patient prognosis; however, mitral
valve surgery does not improve prognosis unless LV function is
improved. MitraClip patients with a 2þ (moderate) MR result have
an improvement in symptoms, functional capacity, and ventricular
size. These ﬁndings suggest that moderate MR (EROA of >0.20
and <0.30 cm2) does not adversely affect either the left ventricle or
patient prognosis and should not be classiﬁed as severe, despite the
most recent ESC guideline/recommendations (1).
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Physical Exercise Reduces
Aortic Regurgitation
Exercise Magnetic Resonance Imaging
In patients with aortic regurgitation (AR), exercise testing plays a
pivotal role in clinical decision making according to American
College of Cardiology/American Heart Association guidelines.
However, it is unclear exactly how AR behaves during exercise, as it
has only been estimated but not measured so far. Using cardiac
magnetic resonance (CMR), it is theoretically possible to measure
AR and cardiac volume changes during exercise. Studies in patients
with other cardiac diseases have combined exercise and CMR by
using complex, cumbersome, and expensive ergometers (1–3).
Therefore, the ﬁrst aim of this study was to establish a simple and
adequate form of exercise during CMR studies. We designed a
steady-state submaximal exercise test, because it is known that most
hemodynamic changes occur at submaximal exercise levels (4).
Additionally, acquiring blood-ﬂow and cardiac-volume data byCMR
requires a certain amount of time during a hemodynamic steady-state.
The second aim of this study was to investigate the change of AR
and left ventricular (LV) volumes during steady-state submaximal
exercise in patients with asymptomatic isolated AR without any
cardiac medication.
To this end, we designed and built an exercise apparatus (patent
utility no. 202013006749.7) to easily enable steady-state submaxi-
mal exercise over longer periods of time during CMR scanning. The
apparatus is intrinsically auto-normative, as the workload depends
only on the length and weight of the subject’s legs, which are
attached to a rope passing over a pulley ﬁxed to a specially designed
aluminum frame mounted onto the magnetic resonance table. The
patients stroke their legs 72 times/min as directed by a metronome.
Healthy volunteers underwent 2 cardiopulmonary tests to
determine steady-state submaximal and peak oxygen uptake (VO2)
by the new submaximal exercise apparatus and by routine symptom-
limited maximal bicycle exercise. Submaximal VO2 was median 24%
(range 17% to 37%) of peak VO2 (8.6 ml/kg/min [range 7.2 to 13.7
ml/kg/min] and 40 ml/kg/min [range 33 to 54 ml/kg/min]).
